Returning raw genomic data to research participants in a pediatric cancer precision medicine trial.

IF 4.7 2区医学 Q1 GENETICS & HEREDITY

NPJ Genomic Medicine Pub Date : 2025-02-17 DOI:10.1038/s41525-025-00470-y

Kristine Barlow-Stewart, Eliza Courtney, Mark Cowley, Camron Ebzery, Noemi Fuentes Bolanos, Andrew J Gifford, Hazel Harden, Sarah Josephi-Taylor, Rishi S Kotecha, Marion K Mateos, Mitali Manzur, Chelsea Mayoh, Dianne Milnes, Jane Nielsen, Matthew O'Connor, Bhavna Padhye, Catherine Pitman, Elizabeth Pitman, Mark Pinese, Catherine Speechly, Ashleigh Sullivan, Toby Trahair, Katherine Tucker, Vanessa Tyrrell, Meera Warby, Andrew Wood, David S Ziegler, Carolyn Johnston

{"title":"Returning raw genomic data to research participants in a pediatric cancer precision medicine trial.","authors":"Kristine Barlow-Stewart, Eliza Courtney, Mark Cowley, Camron Ebzery, Noemi Fuentes Bolanos, Andrew J Gifford, Hazel Harden, Sarah Josephi-Taylor, Rishi S Kotecha, Marion K Mateos, Mitali Manzur, Chelsea Mayoh, Dianne Milnes, Jane Nielsen, Matthew O'Connor, Bhavna Padhye, Catherine Pitman, Elizabeth Pitman, Mark Pinese, Catherine Speechly, Ashleigh Sullivan, Toby Trahair, Katherine Tucker, Vanessa Tyrrell, Meera Warby, Andrew Wood, David S Ziegler, Carolyn Johnston","doi":"10.1038/s41525-025-00470-y","DOIUrl":null,"url":null,"abstract":"<p><p>In pediatric cancer precision medicine clinical trials settings, parents proactively seeking treatment and answers to causation may request return of their child's raw data and/or biospecimen. To satisfy such requests, the ZERO Childhood Cancer Program required a guidance document. Literature review led to Version(V)1; Delphi consultation with 21/54 invited experts (V2-4) and parent consultations (V5-6). A final V7 was approved for implementation: Policy (purpose; background; ethical considerations), Process (nine steps), and consent form. Issues addressed included: child's best interests, clinical utility, non-maleficence, reciprocity between researchers and participants/parents; responsibility to genetic relatives; acknowledging potential value of subsequent analysis/interpretation but no obligation on treating clinicians to act on therapeutic recommendations arising; practical barriers to return; and supporting parental empowerment by facilitating meeting with a study genetic counselor, separate from their treating clinician, if preferred, to manage their request. This guide may be a model for other research groups and inform ethical guidelines.</p>","PeriodicalId":19273,"journal":{"name":"NPJ Genomic Medicine","volume":"10 1","pages":"12"},"PeriodicalIF":4.7000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11832931/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Genomic Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41525-025-00470-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

In pediatric cancer precision medicine clinical trials settings, parents proactively seeking treatment and answers to causation may request return of their child's raw data and/or biospecimen. To satisfy such requests, the ZERO Childhood Cancer Program required a guidance document. Literature review led to Version(V)1; Delphi consultation with 21/54 invited experts (V2-4) and parent consultations (V5-6). A final V7 was approved for implementation: Policy (purpose; background; ethical considerations), Process (nine steps), and consent form. Issues addressed included: child's best interests, clinical utility, non-maleficence, reciprocity between researchers and participants/parents; responsibility to genetic relatives; acknowledging potential value of subsequent analysis/interpretation but no obligation on treating clinicians to act on therapeutic recommendations arising; practical barriers to return; and supporting parental empowerment by facilitating meeting with a study genetic counselor, separate from their treating clinician, if preferred, to manage their request. This guide may be a model for other research groups and inform ethical guidelines.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Genomic Medicine Biochemistry, Genetics and Molecular Biology-Molecular Biology

CiteScore

9.40

自引率

1.90%

发文量

审稿时长

17 weeks

期刊介绍： npj Genomic Medicine is an international, peer-reviewed journal dedicated to publishing the most important scientific advances in all aspects of genomics and its application in the practice of medicine. The journal defines genomic medicine as "diagnosis, prognosis, prevention and/or treatment of disease and disorders of the mind and body, using approaches informed or enabled by knowledge of the genome and the molecules it encodes." Relevant and high-impact papers that encompass studies of individuals, families, or populations are considered for publication. An emphasis will include coupling detailed phenotype and genome sequencing information, both enabled by new technologies and informatics, to delineate the underlying aetiology of disease. Clinical recommendations and/or guidelines of how that data should be used in the clinical management of those patients in the study, and others, are also encouraged.